Project title: DUAL-ACTION INTRAVENOUS (IV) CATHETER

Company name : ACTIVEIN LTD.

TECHNOLOGICAL FIELD
Medical devices

KEY WORDS
Catheter, Intravenous, IV, Blood,
Sampling, Infusion, Needlestick

PROJECT SUMMARY
ActiVein is developing a patented, dual-action intravenous (IV)
catheter that aims to replace the standard conventional "hospital
IV line" by enabling both fluid infusion and blood withdrawal
using a single vein over an entire hospitalization period,
whereas the currently used device allows, regularly, fluid
infusion only.
An IV catheter is inserted in at least one body vein of every
patient throughout the world upon hospitalization. It is used for
delivering fluids to the patient's blood stream. Due to various
physiological and biological reasons, withdrawal of blood samples
cannot be done through the same catheter. This means that at
least once daily, the same patient is subjected to puncturing
attempts in other skin areas, in the course of routine blood
withdrawal rounds for lab test sampling. This routine is a
costly, labor-intensive, time consuming and even risky job. Not
only does it subject the patient to more complications such as
hematomas, local infections and pain, but it also subjects
healthcare workers to the threats of needlestick injuries,
exposing them to infectious diseases such as several types of
Hepatitis and HIV.
Eliminating a major portion of needlestick punctures means a
great reduction in hospital costs. Not only does it free up
medical staff's work time, but it also saves costs of
post-exposure treatment for healthcare workers exposed to
infectious diseases following needlestick injuries, liability and
compensation costs, wages and time lost by these workers.

MARKET
According to a US General Accounting Office (GAO) report, 111
million conventional IV catheters were used in the year 2000 in
US hospitals alone (accounting for about 40% of the US market).
Additional 640 Million IV needles were used in the same year, for
the same group of patients. Standard IV catheters used today are
priced at a range of US$0.4 to US$0.9, depending on quality and
quantities ordered, ActiVein catheter would compete in this price
range. A published researches stated that the US market for IV
catheters totaled US$685 million in 2004 and is expected a growth
of 8.5% to reach just above US$1 billion in 2009.

ENTREPRENEURS
Mr. Adi Plaschkes - CEO Bsc. in
Mechanical Engineering, experience in inventing and developing
medical devices.
Dr. Yoav Paz - CMD, MD, a
senior surgeon at Hadassah-Hebrew University Medical Center in
Jerusalem, has been involved in other novel ideas in the medical
field, some of which have been commercially implemented.
Mr. Ilan Shalev - CTO, Bsc. in
Mechanical Engineering from Tel Aviv University. Vast experience
in product development in general and especially in medical
devices.

PROJECT STATUS
ActiVein started its Incubator period in November 2006.
The ActiVein IV catheter is currently undergoing a process of
final design. The first prototype had been manufactured and has
been successfully tested in animal trials, thus validating the
proprietary concept. The current efforts are concentrated on
building a small series of functional products using various
technologies and testing them.
ActiVein IV catheter received a patent approval under the
name"Vascular Coupling Device" No 03710201.9 in the European
patent office and had been registered in major countries in
Europe.
The US patent approval is on the final examination stage and is
expected to be approved in the near future.

COOPERATION REQUIRED
ActiVein is looking for cooperation with a production facility
that can produce small quantities as well as high volume. In
addition ActiVein is looking for strategic partners and
investments.

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about